Janney Montgomery Scott’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.55M Buy
27,427
+4,913
+22% +$286K ﹤0.01% 1413
2025
Q4
$1.34M Buy
22,514
+11,965
+113% +$651K ﹤0.01% 1568
2025
Q3
$571K Buy
10,549
+14
+0.1% +$801 ﹤0.01% 2060
2025
Q2
$579K Sell
10,535
-1,481
-12% -$87.2K ﹤0.01% 1925
2025
Q1
$849K Buy
12,016
+4,345
+57% +$292K ﹤0.01% 1649
2024
Q4
$504K Sell
7,671
-4,029
-34% -$270K ﹤0.01% 1993
2024
Q3
$822K Buy
11,700
+5,911
+102% +$494K ﹤0.01% 1635
2024
Q2
$477K Sell
5,789
-2,633
-31% -$219K ﹤0.01% 1925
2024
Q1
$736K Sell
8,422
-266
-3% -$23.8K ﹤0.01% 1704
2023
Q4
$837K Sell
8,688
-280
-3% -$24.8K ﹤0.01% 1551
2023
Q3
$793K Sell
8,968
-57
-0.6% -$5.07K ﹤0.01% 1463
2023
Q2
$782K Sell
9,025
-133
-1% -$12.5K ﹤0.01% 1563
2023
Q1
$891K Sell
9,158
-1,451
-14% -$150K ﹤0.01% 1386
2022
Q4
$1.1M Sell
10,609
-383
-3% -$36K ﹤0.01% 1316
2022
Q3
$932K Buy
10,992
+1,603
+17% +$143K ﹤0.01% 1347
2022
Q2
$780K Sell
9,389
-3,354
-26% -$267K ﹤0.01% 1368
2022
Q1
$982K Sell
12,743
-22,197
-64% -$1.86M ﹤0.01% 1258
2021
Q4
$3.09M Sell
34,940
-853
-2% -$70.4K 0.01% 794
2021
Q3
$2.77M Buy
35,793
+1,641
+5% +$129K 0.01% 806
2021
Q2
$2.85M Buy
34,152
+9,098
+36% +$721K 0.01% 793
2021
Q1
$1.89M Buy
25,054
+1,175
+5% +$96K 0.01% 914
2020
Q4
$2.09M Sell
23,879
-6,682
-22% -$530K 0.01% 852
2020
Q3
$2.33M Sell
30,561
-32,427
-51% -$3.28M 0.01% 754
2020
Q2
$7.77M Buy
62,988
+43,750
+227% +$4.35M 0.05% 331
2020
Q1
$1.63M Buy
19,238
+1,751
+10% +$151K 0.01% 768
2019
Q4
$1.48M Sell
17,487
-1,371
-7% -$104K 0.01% 905
2019
Q3
$1.27M Buy
18,858
+7,061
+60% +$544K 0.01% 930
2019
Q2
$1.01M Buy
11,797
+4,857
+70% +$415K 0.01% 1044
2019
Q1
$616K Buy
6,940
+268
+4% +$24.8K 0.01% 1274
2018
Q4
$568K Sell
6,672
-1,823
-21% -$173K 0.01% 1221
2018
Q3
$824K Sell
8,495
-800
-9% -$79.9K 0.01% 1151
2018
Q2
$876K Sell
9,295
-1,450
-13% -$127K 0.01% 1052
2018
Q1
$871K Buy
10,745
+1,264
+13% +$108K 0.01% 1031
2017
Q4
$845K Sell
9,481
-774
-8% -$67.3K 0.01% 1035
2017
Q3
$954K Sell
10,255
-1,310
-11% -$116K 0.01% 956
2017
Q2
$1.05M Sell
11,565
-771
-6% -$70.1K 0.01% 848
2017
Q1
$1.08M Buy
12,336
+550
+5% +$48.9K 0.01% 807
2016
Q4
$976K Sell
11,786
-1,795
-13% -$154K 0.01% 784
2016
Q3
$1.26M Buy
+13,581
New +$1.28M 0.02% 574
2016
Q2
Sell
-7,365
Closed -$607K 723
2016
Q1
$607K Sell
7,365
-1,616
-18% -$131K 0.02% 698
2015
Q4
$941K Sell
8,981
-1,904
-17% -$199K 0.02% 567
2015
Q3
$1.15M Sell
10,885
-920
-8% -$123K 0.03% 492
2015
Q2
$1.61M Buy
11,805
+846
+8% +$105K 0.03% 573
2015
Q1
$1.37M Buy
10,959
+2,076
+23% +$220K 0.03% 724
2014
Q4
$803K Buy
8,883
+499
+6% +$41.5K 0.02% 978
2014
Q3
$605K Buy
8,384
+800
+11% +$52.6K 0.01% 1139
2014
Q2
$472K Buy
+7,584
New +$458K 0.01% 1279

Other funds holding BMRN

Janney Montgomery Scott's BMRN Position: Q1 2026 in Review

Janney Montgomery Scott increased its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q1 2026, buying an estimated $286K and bringing the position to 27,427 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Janney Montgomery Scott first reported a position in BMRN in Q2 2014 and has held it in 47 quarters since. The position peaked at $7.77M in Q2 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Janney Montgomery Scott held 27,427 shares of BioMarin Pharmaceuticals worth $1.55M as of Q1 2026.
  • Janney Montgomery Scott bought 4,913 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $286K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q1 2026, its #1413 holding.
  • Janney Montgomery Scott first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 47 quarters since.
  • Janney Montgomery Scott's BioMarin Pharmaceuticals position peaked at $7.77M in Q2 2020.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Janney Montgomery Scott's 13F filing for Q1 2026, filed 22 Apr 2026.